Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All casirivimab/imdevimab..
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchCasirivimab/imdevimabCasirivimab/i.. (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Doubtful Clinical Benefit of Casirivimab-Imdevimab Treatment for Disease Severity Outcome of High-Risk Patients with SARS-CoV-2 Delta Variant Infection

Shopen et al., medRxiv, doi:10.1101/2022.01.29.22270090
Jan 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Severe case -46% Improvement Relative Risk Casirivimab/i..  Shopen et al.  EARLY TREATMENT Is early treatment with casirivimab/imdevimab beneficial for COVID-19? Retrospective 359 patients in Israel (June - September 2021) Higher severe cases with casirivimab/imdevimab (not stat. sig., p=0.26) c19early.org Shopen et al., medRxiv, January 2022 Favorscasirivimab/im.. Favorscontrol 0 0.5 1 1.5 2+
16th treatment shown to reduce risk in March 2021
 
*, now with p = 0.000055 from 29 studies, recognized in 45 countries. Efficacy is variant dependent.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 75 treatments. c19early.org
Retrospective 359 COVID+ patients in Israel, 116 treated with casirivimab/imdevimab, showing no significant difference with treatment in multivariable analysis.
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for many omicron variants1-6.
risk of severe case, 45.6% higher, RR 1.46, p = 0.26, treatment 24 of 116 (20.7%), control 26 of 243 (10.7%), adjusted per study, odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Shopen et al., 31 Jan 2022, retrospective, Israel, preprint, 11 authors, study period June 2021 - September 2021.
This PaperCasirivimab/i..All
Doubtful Clinical Benefit of Casirivimab-Imdevimab Treatment for Disease Severity Outcome of High-Risk Patients with SARS-CoV-2 Delta Variant Infection
Noah Shopen, Michal Dekel, Michal Mizrahi, Efrat Zandberg, Nancy Bishouty, Daniel Talmud, Ben Vaknin, Shira Haberman, Malka Katz Shalhav, David Zeltser, MD Neta Cohen
doi:10.1101/2022.01.29.22270090
Casirivimab/Imdevimab therapy reportedly retains neutralization potency against circulating SARS-CoV-2 variants, including Delta (B.1.617.2), but there are sparse data on its clinical benefit against the Delta variant among vaccinated and unvaccinated patients. We explored its therapeutic effect on COVID-19 severity outcome in terms of room air saturation <93% within 14 days of initial presentation and 45-day all-cause mortality among high-risk patients with SARS-CoV-2 Delta variant infection and compared its effect between vaccinated and unvaccinated patients. We conducted a retrospective cohort study at a tertiary care medical center between 6/2021 and 9/2021 and included patients who presented with a positive PCR for SARS-CoV-2 and fulfilled the criteria for Casirivimab/Imdevimab treatment. Of the 359 suitable patients (52% female, median age 63 years), 116 were treated with Casirivimab/Imdevimab and 243 were not. Two-hundred and one (56%) patients had received at least 2 SARS-CoV-2 vaccinations. Casirivimab/Imdevimab treatment was not an independent protective factor of COVID-19 severity outcome (multivariable analysis). Chronic kidney disease (aOR=3.51 [95%CI: 1.34-9.20], P=0.01), lower saturation levels (aOR=0.7 [95%CI: 0.58-0.85], P<0.01), abnormal chest x-ray findings (aOR=2.92, [95%CI: 1.24-6.87, P=0.01), and higher C-reactive protein levels (aOR=1.01 [95%CI: 1.00-1.01], P=0.008) were independent risk factors of COVID-19 severity. Positive immunization status was an independent protective factor (aOR=0.33 [95%CI: 0.14-0.77], P=0.01). A sub analysis of patients treated with Casirivimab/Imdevimab revealed no significant difference in COVID-19 severity between vaccinated and unvaccinated patients. These findings demonstrate no added benefit of Casrivimab/Imdevinab treatment for high-risk patients with the SARS-CoV-2 Delta variant infection, regardless of their vaccination status.
References
Balbi, Caroli, Corsi, Milanese, Surace et al., Chest X-ray for predicting mortality and the need for ventilatory support in COVID-19 patients presenting to the emergency department, Eur Radiol, doi:10.1007/s00330-020-07270-1
Baum, Fulton, Wloga, Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies, Science
Bierle, Ganesh, Tulledge-Scheitel, Monoclonal Antibody Treatment of Breakthrough COVID-19 in Fully Vaccinated Individuals with High-Risk Comorbidities
Bierle, Ganesh, Wilker, Hanson, Moehnke et al., Influence of Social and Cultural Factors on the Decision to Consent for Monoclonal Antibody Treatment among High-Risk Patients with Mild-Moderate COVID-19, J Prim Care Community Health, doi:10.1177/21501327211019282
Cameroni, Saliba, Bowen, Rosen, Culap et al., Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift bioRxiv, doi:10.1101/2021.12.12.472269
Casirivimab + Imdevimab Injection, Elliott, William, Chan, None, Internal Medicine Alert and Atlanta
Copin, Baum, Wloga, The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies, Cell
Cozzi, Albanesi, Cavigli, Moroni, Bindi et al., Chest X-ray in new Coronavirus Disease 2019 (COVID-19) infection: findings and correlation with clinical outcome, Radiol Med, doi:10.1007/s11547-020-01232-9
Docherty, Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterization Protocol: prospective observational cohort study, BMJ
Embi, Levy, Naleway, Patel, Gaglani et al., Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults -Nine States, January, MMWR Morbidity and mortality weekly report
Falcone, Tiseo, Valoriani, Efficacy of Bamlanivimab/Etesevimab and Casirivimab/Imdevimab in Preventing Progression to Severe COVID-19 and Role of Variants of Concern, Infect Dis Ther, doi:10.1007/s40121-021-00525-4
Fda, Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19
Ganesh, Philpot, Bierle, Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019, J Infect Dis, doi:10.1093/infdis/jiab377
Gao, Dong, Risk Factors for Severe and Critically Ill COVID 19 Patients: A Review, Allergy (Copenhagen)
Gottlieb, Nirula, Chen, Boscia, Heller et al., Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial, JAMA, doi:10.1001/jama.2021.0202
Haas, Angulo, Mclaughlin, Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data, Lancet
He, He, Hong, Zhang, Wei, The challenges of COVID-19 Delta variant: Prevention and vaccine development
Horby, Mafham, Peto, Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Mair, Berger, Berghoff, Starzer, Ortmayr et al., Humoral Immune Response in Hematooncological Patients and Health Care Workers Who Received SARS-CoV-2 Vaccinations, JAMA Oncology
Marrams, Kobayashi, Suzuki, patients: a systematic literature review and meta-analysis
Planas, Saunders, Maes, Guivel-Benhassine, Planchais et al., Considerable escape of SARS-CoV-2 variant Omicron to antibody neutralization, bioRxiv, doi:10.1101/2021.12.14.472630
Tabata, Clinical characteristics of COVID-19 in 104 people with SARS-CoV-2 infection on the Diamond Princess cruise ship: a retrospective analysis, Lancet Infect. Dis
Von Elm, Altman, Egger, Pocock, Gøtzsche et al., The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies, Lancet
Wang, Nair, Liu, Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7, Nature
Weinreich, Sivapalasingam, Norton, REGEN-COV antibody cocktail clinical outcomes study in Covid-19 outpatients, doi:10.1101/2021.05.19.21257469v2
Weinreich, Sivapalasingam, Norton, REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19, N Engl J Med
Weinreich, Sivapalasingam, Norton, REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19, N Engl J Med
Williamson, Walker, Bhaskaran, Factors associ-ated with COVID-19-related death using OpenSAFELY, Nature
Zhang, Cao, Tan, Clinical, radiological, and laboratory characteristics and risk factors for severity and mortality of 289 hospitalized COVID-19 patients, Allergy
{ 'institution': [{'name': 'medRxiv'}], 'indexed': {'date-parts': [[2022, 1, 31]], 'date-time': '2022-01-31T21:41:28Z', 'timestamp': 1643665288563}, 'posted': {'date-parts': [[2022, 1, 31]]}, 'group-title': 'Emergency Medicine', 'reference-count': 0, 'publisher': 'Cold Spring Harbor Laboratory', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'short-container-title': [], 'accepted': {'date-parts': [[2022, 1, 31]]}, 'abstract': '<jats:p>Casirivimab/Imdevimab therapy reportedly retains neutralization potency against ' 'circulating SARS-CoV-2 variants, including Delta (B.1.617.2), but there are sparse data on ' 'its clinical benefit against the Delta variant among vaccinated and unvaccinated patients. We ' 'explored its therapeutic effect on COVID-19 severity outcome in terms of room air saturation ' '&lt;93% within 14 days of initial presentation and 45 day all cause mortality among high-risk ' 'patients with SARS-CoV-2 Delta variant infection and compared its effect between vaccinated ' 'and unvaccinated patients. We conducted a retrospective cohort study at a tertiary care ' 'medical center between 6/2021 and 9/2021 and included patients who presented with a positive ' 'PCR for SARS-CoV-2 and fulfilled the criteria for Casirivimab/Imdevimab treatment. Of the 359 ' 'suitable patients (52% female, median age 63 years), 116 were treated with ' 'Casirivimab/Imdevimab and 243 were not. Two hundred and one (56%) patients had received at ' 'least 2 SARS-CoV-2 vaccinations. Casirivimab/Imdevimab treatment was not an independent ' 'protective factor of COVID 19 severity outcome (multivariable analysis). Chronic kidney ' 'disease (aOR=3.51 [95%CI: 1.34 to 9.20], P=0.01), lower saturation levels (aOR=0.7 [95%CI: ' '0.58 to 0.85], P&lt;0.01), abnormal chest x ray findings (aOR=2.92, [95%CI: 1.24 to 6.87, ' 'P=0.01), and higher C-reactive protein levels (aOR=1.01 [95%CI: 1.00 to 1.01], P=0.008) were ' 'independent risk factors of COVID-19 severity. Positive immunization status was an ' 'independent protective factor (aOR=0.33 [95%CI: 0.14 to 0.77], P=0.01). A sub analysis of ' 'patients treated with Casirivimab/Imdevimab revealed no significant difference in COVID-19 ' 'severity between vaccinated and unvaccinated patients. These findings demonstrate no added ' 'benefit of Casrivimab/Imdevinab treatment for high-risk patients with the SARS-CoV-2 Delta ' 'variant infection, regardless of their vaccination status.</jats:p>', 'DOI': '10.1101/2022.01.29.22270090', 'type': 'posted-content', 'created': {'date-parts': [[2022, 1, 31]], 'date-time': '2022-01-31T21:10:26Z', 'timestamp': 1643663426000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': [ 'Doubtful Clinical Benefit of Casirivimab-Imdevimab Treatment for Disease Severity Outcome of ' 'High-Risk Patients with SARS-CoV-2 Delta Variant Infection'], 'prefix': '10.1101', 'author': [ {'given': 'Noah', 'family': 'Shopen', 'sequence': 'first', 'affiliation': []}, {'given': 'Michal', 'family': 'Dekel', 'sequence': 'additional', 'affiliation': []}, {'given': 'Michal', 'family': 'Mizrahi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Efrat', 'family': 'Zandberg', 'sequence': 'additional', 'affiliation': []}, {'given': 'Nancy', 'family': 'Bishouty', 'sequence': 'additional', 'affiliation': []}, {'given': 'Daniel', 'family': 'Talmud', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ben', 'family': 'Vaknin', 'sequence': 'additional', 'affiliation': []}, {'given': 'Shira', 'family': 'Haberman', 'sequence': 'additional', 'affiliation': []}, {'given': 'Malka', 'family': 'Katz Shalhav', 'sequence': 'additional', 'affiliation': []}, {'given': 'David', 'family': 'Zeltser', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0001-7694-6407', 'authenticated-orcid': False, 'given': 'Neta', 'family': 'Cohen', 'sequence': 'additional', 'affiliation': []}], 'member': '246', 'container-title': [], 'original-title': [], 'link': [ { 'URL': 'https://syndication.highwire.org/content/doi/10.1101/2022.01.29.22270090', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 1, 31]], 'date-time': '2022-01-31T21:10:26Z', 'timestamp': 1643663426000}, 'score': 1, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 1, 31]]}, 'references-count': 0, 'URL': 'http://dx.doi.org/10.1101/2022.01.29.22270090', 'relation': {}, 'published': {'date-parts': [[2022, 1, 31]]}, 'subtype': 'preprint'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit